Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 08 May 2018
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure; Hyponatraemia
- Focus Therapeutic Use
- 30 Apr 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 30 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated